Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients with Chronic Inflammatory Demyelinating Polyneurop

This project, presented as an Open-label Extension of the ARGX-113-1802 trial focuses on efgartigimod PH20 SC in patients with chronic inflammatory demyelinating polyneuropathy (CIDP), with primary aims described in the project title: to investigate long-term safety, tolerability and efficacy.

The Open-label Extension design allows continued observation of participants who previously received investigational therapy and assessment of prolonged exposure to efgartigimod PH20 SC and the durability of treatment effects over time. This follow-on study provides an opportunity to monitor longer-term outcomes, capture extended safety data and evaluate sustained tolerability in a real-world clinical trial setting. While the project title identifies the investigational agent and the targeted disease population, the study's emphasis on safety, tolerability and efficacy highlights its role in defining the long-term clinical profile of efgartigimod PH20 SC for patients with CIDP. As an open-label extension, the research also serves as a bridge between controlled trial results and extended clinical experience, enabling clinicians and investigators to observe ongoing response patterns, adverse event profiles, and practical aspects of subcutaneous administration over prolonged periods.

This study aligns with a translational research approach: moving from initial trial findings toward sustained clinical evaluation and informing future therapeutic decision-making. For patients living with CIDP, long-term data on a targeted agent such as efgartigimod PH20 SC are critical to understanding whether benefits are maintained, how tolerability evolves and what safety signals may emerge with extended exposure.